LIFECORE BIOMEDICAL INC (LFCR) Stock Overview
USA - NASDAQ:LFCR - US5147661046 - Common Stock
LFCR Key Statistics, Chart & Performance
The current stock price of LFCR is 6.84 USD. In the past year, price increased by 23.93%.
LFCR Latest News, Press Relases and Analysis
LFCR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.62 | 216.73B | ||
| DHR | DANAHER CORP | 28.97 | 159.92B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 148.68 | 48.50B | ||
| A | AGILENT TECHNOLOGIES INC | 27.13 | 41.92B | ||
| IQV | IQVIA HOLDINGS INC | 19.23 | 37.51B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.08 | 29.55B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 42.55 | 21.63B | ||
| WAT | WATERS CORP | 29.32 | 21.35B | ||
| MEDP | MEDPACE HOLDINGS INC | 42.45 | 17.05B | ||
| ILMN | ILLUMINA INC | 24.2 | 15.48B | ||
| TEM | TEMPUS AI INC | N/A | 15.74B | ||
| ICLR | ICON PLC | 13.28 | 13.62B |
Related stock screener links
About LFCR
Company Profile
Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. The company is headquartered in Chaska, Minnesota and currently employs 406 full-time employees. The firm designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The firm offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. The company is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The firm uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
Company Info
LIFECORE BIOMEDICAL INC
3515 Lyman Boulevard
Chaska MINNESOTA US
Employees: 524
Phone: 19523684300
LIFECORE BIOMEDICAL INC / LFCR FAQ
What does LFCR do?
Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. The company is headquartered in Chaska, Minnesota and currently employs 406 full-time employees. The firm designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The firm offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. The company is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The firm uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
What is the stock price of LIFECORE BIOMEDICAL INC today?
The current stock price of LFCR is 6.84 USD. The price increased by 0.44% in the last trading session.
What is the dividend status of LIFECORE BIOMEDICAL INC?
LFCR does not pay a dividend.
How is the ChartMill rating for LIFECORE BIOMEDICAL INC?
LFCR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of LIFECORE BIOMEDICAL INC (LFCR)?
LIFECORE BIOMEDICAL INC (LFCR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.27).
Can you provide the market cap for LIFECORE BIOMEDICAL INC?
LIFECORE BIOMEDICAL INC (LFCR) has a market capitalization of 256.29M USD. This makes LFCR a Micro Cap stock.
What is the Short Interest ratio of LIFECORE BIOMEDICAL INC (LFCR) stock?
The outstanding short interest for LIFECORE BIOMEDICAL INC (LFCR) is 7.32% of its float.
LFCR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to LFCR. When comparing the yearly performance of all stocks, LFCR turns out to be only a medium performer in the overall market: it outperformed 62.4% of all stocks.
LFCR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LFCR. LFCR has a bad profitability rating. Also its financial health evaluation is rather negative.
LFCR Financial Highlights
Over the last trailing twelve months LFCR reported a non-GAAP Earnings per Share(EPS) of -1.27. The EPS decreased by -669.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.53% | ||
| ROE | -93.52% | ||
| Debt/Equity | 2.68 |
LFCR Forecast & Estimates
10 analysts have analysed LFCR and the average price target is 10.2 USD. This implies a price increase of 49.12% is expected in the next year compared to the current price of 6.84.
For the next year, analysts expect an EPS growth of 41.64% and a revenue growth 3.51% for LFCR